Business
Nasus Pharma Announces Closing of $15.0 Million Private Placement
TEL AVIV, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced the closing of its previously announced private placement of ordinary shares and warrants to purchase ordinary shares for aggregate gross proceeds of approximately $15.0 million, before deducting placement agent fees and other offering expenses. Citizens Capital Markets a
About this update from Nasus Pharma Ltd.
[{"type":"image","alt":"Nasus Pharma, Ltd.","displaySize":"","headline":null,"caption":"Nasus Pharma, Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":241,"height":136,"url":"https://media.zenfs.com/en/globenewswire.com/f80d312befe1c63984fc7bf025e58d6d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/quoV9o_G7y0qGuyE83dEZQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzNztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f80d312befe1c63984fc7bf025e58d6d","width":241,"height":136}},"lazy":false},{"type":"text","content":"TEL AVIV, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced the closing of its previously announced private placement of ordinary shares and warrants to purchase ordinary shares for aggregate gross proceeds of approximately $15.0 million, before deducting placement agent fees and other offering expenses.","length":493,"tagName":"p"},{"type":"text","content":"Citizens Capital Markets acted as lead placement agent, and Laidlaw & Company (UK) Ltd. acted as co-placement agent, in connection with the private placement.","length":162,"tagName":"p"},{"type":"text","content":"“We believe this financing strengthens our balance sheet as we advance NS002, our powder-based intranasal epinephrine product candidate, towards a pivotal study and New Drug Application (“NDA”) submission while continuing to expand our pipeline of innovative, intranasal, powder-based programs,” said Dan Teleman, Chief Executive Officer of Nasus Pharma. “NS002 is an important step in demonstrating the potential of our platform, and beyond this program we are focused on applying our proprietary intranasal technology across additional therapeutic areas. Our objective is to develop products where intranasal administration could add clinically meaningful value.”","length":665,"tagName":"p"},{"type":"text","content":"Eyal Rubin, Chief Financial Officer of Nasus Pharma, added: “We are grateful for the strong participation from both new and existing investors including leading institutional investors, in this financing. The proceeds from this private placement are expected to significantly strengthen our balance sheet and provide funding visibility across our planned...